1. American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
3. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and metaanalysis. Pediatrics 2015;135:e994-e1001.
4. Ercan ES, Polanczyk G, Akyol Ardıc U, Yuce D, Karacetın G, Tufan AE, et al. The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nord J Psychiatry 2019;73:132-140.
6. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet 2015;6736:1-11.
10. Leffa DT, Torres ILS, Rohde LA. A review on the role of nflammation in attention-deficit/hyperactivity disorder. Neuroimmunomodulation 2018;25:328-333.
11. Donfrancesco R, Nativio P, Di Benedetto A, Villa MP, Andriola E, Melegari MG, et al. Anti-yo antibodies in children with ADHD. J Atten Disord pii: 1087054716643387. [Epub ahead of print].
12. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-20810.
13. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008;10:e17
14. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-635.
15. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 2002;19:575-581.
17. Venkatraman A, Callas P, McClure LA, Unverzagt F, Arora G, Howard V, et al. Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites. Alzheimer’s Dement Transl Res Clin Interv 2018;4:165-172.
18. Doverhag C, Hedtjärn M, Poirier F, Mallard C, Hagberg H, Karlsson A, et al. Galectin-3 contributes to neonatal hypoxic-ischemic brain injury. Neurobiol Dis 2010;38:36-46.
19. Rahimian R, Béland LC, Kriz J. Galectin-3: mediator of microglia responses in injured brain. Drug Discov Today 2018;23:375-381.
24. Gökler B, Ünal F, Pehlivantürk B, Cengel Kultur E, Devrim Akdemir D, Taner Y. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turkish J Child Adolesc Ment Heal 2004;11:109-116.
25. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-988.
26. Ercan ES, Amado S, Somer O, Çıkoğlu S. Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. J Child Adolesc Ment Health 2001;8:132-144.
27. Turgay A. Disruptive Behavior Disorders Child and Adolescent Screening and Rating Scales for Children, Adolescents, Parents and Teachers. West Bloomfield, MI: Michigan Integrative Therapy Institute Publication; 1994.
28. Gormez V, Kılınçaslan A, Cahid Orengul A, Ebesutani C, Kaya I, Ceri V, et al. Psychometric properties of the Turkish version of the Revised Child Anxiety and Depression Scale-Child Version in a clinical sample. Psychiatry Clin Psychopharmacol 2017;27:84-92.
30. Boscher C, Dennis JW, Nabi IR. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol 2011;23:383-392.
31. Yu F, Finley RL, Raz A, Kim HRC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002;277:15819-15827.
32. Darwish AH, Elgohary TM, Nosair NA. Serum interleukin-6 level in children with attention-deficit hyperactivity disorder (ADHD). J Child Neurol 2019;34:61-67.
34. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 2009;182:1167-1173.